$CARA
Cara Therapeutics, Inc.

2015 Q4 Form 10-K Financial Statement

#000119312516500345 Filed on March 11, 2016

View on sec.gov

Income Statement

Concept 2015 Q4 2014 Q4 2014 Q3
Revenue $0.00 $914.0K $1.125M
YoY Change -100.0% -6.06% 10.51%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.200M $1.800M $1.500M
YoY Change 22.22% 63.64% 87.5%
% of Gross Profit
Research & Development $7.600M $3.500M $6.208M
YoY Change 117.14% 75.0% 64.93%
% of Gross Profit
Depreciation & Amortization $260.0K $190.0K $200.0K
YoY Change 36.84% -5.0% 5.26%
% of Gross Profit
Operating Expenses $9.700M $5.300M $7.728M
YoY Change 83.02% 70.97% 69.51%
Operating Profit -$6.603M
YoY Change 86.47%
Interest Expense $100.0K $0.00 $26.00K
YoY Change -102.51%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$9.700M -$4.300M -$6.577M
YoY Change 125.58% 104.76% 43.76%
Income Tax -$100.0K -$100.0K -$32.00K
% Of Pretax Income
Net Earnings -$9.530M -$4.172M -$6.545M
YoY Change 128.43% 98.67% 43.06%
Net Earnings / Revenue -456.46% -581.78%
Basic Earnings Per Share
Diluted Earnings Per Share -$348.0K -$184.2K -$286.3K
COMMON SHARES
Basic Shares Outstanding 27.23M shares 22.78M shares 22.71M shares
Diluted Shares Outstanding 22.71M shares

Balance Sheet

Concept 2015 Q4 2014 Q4 2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $106.7M $52.70M $58.40M
YoY Change 102.47% 325.0% 229.94%
Cash & Equivalents $15.10M $52.66M $58.39M
Short-Term Investments $91.60M
Other Short-Term Assets $1.700M $300.0K $900.0K
YoY Change 466.67% -85.71% 50.0%
Inventory
Prepaid Expenses $1.729M $287.0K $928.0K
Receivables
Other Receivables
Total Short-Term Assets $108.9M $53.15M $59.41M
YoY Change 104.96% 265.09% 224.64%
LONG-TERM ASSETS
Property, Plant & Equipment $1.263M $2.084M $2.262M
YoY Change -39.4% -26.23% -24.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $700.0K $700.0K $700.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $1.963M $2.784M $2.962M
YoY Change -29.49% -21.02% -22.05%
TOTAL ASSETS
Total Short-Term Assets $108.9M $53.15M $59.41M
Total Long-Term Assets $1.963M $2.784M $2.962M
Total Assets $110.9M $55.93M $62.37M
YoY Change 98.26% 209.32% 182.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.965M $515.0K $1.715M
YoY Change 281.55% -23.82% 31.92%
Accrued Expenses $3.300M $1.400M $2.400M
YoY Change 135.71% 7.69% 100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.268M $3.398M $6.093M
YoY Change 55.03% -37.46% -16.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $600.0K $900.0K $900.0K
YoY Change -33.33% -18.18% -25.0%
Total Long-Term Liabilities $600.0K $900.0K $900.0K
YoY Change -33.33% -18.18% -25.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.268M $3.398M $6.093M
Total Long-Term Liabilities $600.0K $900.0K $900.0K
Total Liabilities $5.900M $4.300M $7.000M
YoY Change 37.21% -34.85% -17.65%
SHAREHOLDERS EQUITY
Retained Earnings -$104.9M -$80.20M -$76.03M
YoY Change 30.79% 28.41%
Common Stock $210.0M $131.9M $23.00K
YoY Change 59.23% 1473.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $105.0M $51.66M $55.34M
YoY Change
Total Liabilities & Shareholders Equity $110.9M $55.93M $62.40M
YoY Change 98.26% 209.03% 182.35%

Cashflow Statement

Concept 2015 Q4 2014 Q4 2014 Q3
OPERATING ACTIVITIES
Net Income -$9.530M -$4.172M -$6.545M
YoY Change 128.43% 98.67% 43.06%
Depreciation, Depletion And Amortization $260.0K $190.0K $200.0K
YoY Change 36.84% -5.0% 5.26%
Cash From Operating Activities -$4.170M -$5.820M -$4.490M
YoY Change -28.35% 15.02% 30.52%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$10.00K -$20.00K
YoY Change 0.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities -$91.66M $0.00
YoY Change
Cash From Investing Activities -$91.67M -$10.00K -$20.00K
YoY Change 916600.0% 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -190.0K 110.0K 90.00K
YoY Change -272.73% -135.48%
NET CHANGE
Cash From Operating Activities -4.170M -5.820M -4.490M
Cash From Investing Activities -91.67M -10.00K -20.00K
Cash From Financing Activities -190.0K 110.0K 90.00K
Net Change In Cash -96.03M -5.720M -4.420M
YoY Change 1578.85% 6.32% 28.49%
FREE CASH FLOW
Cash From Operating Activities -$4.170M -$5.820M -$4.490M
Capital Expenditures -$10.00K -$10.00K -$20.00K
Free Cash Flow -$4.160M -$5.810M -$4.470M
YoY Change -28.4% 15.05% 29.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q3 cara Percentage Of Discount On Conversion Price
PercentageOfDiscountOnConversionPrice
0.10 pure
CY2014Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
29186929 shares
CY2014Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
29186929 shares
CY2016Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27254863 shares
CY2007Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
10.08
CY2007Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
19851 shares
CY2015Q2 dei Entity Public Float
EntityPublicFloat
208552053
CY2012Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
26636118 shares
CY2012Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
26636118 shares
CY2012Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
26636118 shares
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-58133000
CY2012Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
58530000
CY2012Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
58522000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1117000
CY2012Q4 cara Common Stock Issuable Upon Conversion
CommonStockIssuableUponConversion
11594757 shares
CY2013Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
29186929 shares
CY2013Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
29402200 shares
CY2013Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
29186929 shares
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-54075000
CY2013Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
65969000
CY2013Q4 us-gaap Accumulated Amortization Deferred Finance Costs
AccumulatedAmortizationDeferredFinanceCosts
117000
CY2013Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
65586000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12357000
CY2013Q4 cara Common Stock Issuable Upon Conversion
CommonStockIssuableUponConversion
12554171 shares
CY2014Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22802039 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22802039 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
131840000
CY2014Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
504000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
112000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
51662000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
266000
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1946000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
874000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1452000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
515000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80201000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55934000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
23000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6192000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3398000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
32716000
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27094000
CY2014Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1018000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
32716000
CY2014Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
200000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
333000
CY2014Q4 us-gaap Assets
Assets
55934000
CY2014Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
700000
CY2014Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
566000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2084000
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2014Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
18000
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
197000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
53150000
CY2014Q4 us-gaap Prepaid Insurance
PrepaidInsurance
92000
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
287000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52663000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8276000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3508000
CY2014Q4 cara Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
177000
CY2014Q4 cara Accrued Research Projects
AccruedResearchProjects
549000
CY2015Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27254863 shares
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
15 Position
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27254863 shares
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
209943000
CY2015Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1204000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
186000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
105044000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
371000
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5268000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
585000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1965000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-104891000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
110897000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7017000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5268000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
43033000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-35000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
36217000
CY2015Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1206000
CY2015Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
7036000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
91640000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
43033000
CY2015Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
384000
CY2015Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
106740000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1106000
CY2015Q4 us-gaap Assets
Assets
110897000
CY2015Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
700000
CY2015Q4 us-gaap Interest Receivable
InterestReceivable
80000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
57132000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1263000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
57132000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
40000
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
40000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
108934000
CY2015Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
91640000
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
49653000
CY2015Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
35000
CY2015Q4 us-gaap Prepaid Rent
PrepaidRent
96000
CY2015Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
189000
CY2015Q4 us-gaap Prepaid Insurance
PrepaidInsurance
98000
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0
CY2015Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1729000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15101000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8280000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
91675000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
4315000
CY2015Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
49657000
CY2015Q4 cara Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
1500000
CY2015Q4 cara Accrued Research Projects
AccruedResearchProjects
1542000
CY2014Q3 cara Number Of Shares Issued Upon Exercise Of Warrant
NumberOfSharesIssuedUponExerciseOfWarrant
6383 shares
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5750000 shares
CY2014Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
56297000
CY2014Q1 cara Gross Proceeds From Issuance Initial Public Offering
GrossProceedsFromIssuanceInitialPublicOffering
63250000
CY2014Q1 cara Underwriting Discounts And Commissions
UnderwritingDiscountsAndCommissions
6953000
CY2014Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2014Q4 cara Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.00 pure
CY2015Q1 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.03 pure
CY2015Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2015Q4 cara Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.00 pure
CY2015Q4 cara Aggregate Net Proceeds From Equity Financing And Issuance Of Debt
AggregateNetProceedsFromEquityFinancingAndIssuanceOfDebt
204800000
CY2015Q4 cara Upfront And Milestone Payments Earned In Connection With License Agreements
UpfrontAndMilestonePaymentsEarnedInConnectionWithLicenseAgreements
32500000
CY2013Q2 cara Probability Of Closing Equity Offering
ProbabilityOfClosingEquityOffering
0.00 pure
CY2013Q4 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
311000
CY2014Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
12554171 shares
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
2829000
CY2013 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2013 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0142 pure
CY2013 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.4990 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.1204 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0603 pure
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4133138 shares
CY2013 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4133138 shares
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4133138 shares
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0075 pure
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-3963000
CY2013 us-gaap Revenues
Revenues
11964000
CY2013 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
4466000
CY2013 us-gaap Interest Paid
InterestPaid
37000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
123000
CY2013 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
30000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
75000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-237000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3756000
CY2013 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1736000
CY2013 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
307000
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
0
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
0
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3072000
CY2013 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
311000
CY2013 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
70000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3993000
CY2013 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
3432000
CY2013 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
3888000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-30000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
123000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
123000
CY2013 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2013 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3475000
CY2013 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1462000
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
0
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
11240000
CY2013 us-gaap Operating Expenses
OperatingExpenses
12201000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-5000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8416000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8685000
CY2013 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-30000
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
722000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3516000
CY2013 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
117000
CY2013 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2013 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2013 cara Effective Income Tax Rate Reconciliation Stock Option Shortfalls And Cancellations
EffectiveIncomeTaxRateReconciliationStockOptionShortfallsAndCancellations
0.0000 pure
CY2013 cara Fair Value Transfers Between Levels One Two And Three
FairValueTransfersBetweenLevelsOneTwoAndThree
0 Securities
CY2013 cara Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-3072000
CY2013 cara Clinical Compound Revenue
ClinicalCompoundRevenue
102000
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-30000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
789000
CY2013 cara Extinguishment Of Preferred Stock
ExtinguishmentOfPreferredStock
891000
CY2013 cara Collaborative Revenue
CollaborativeRevenue
2225000
CY2013 cara Deferred Rent Liability Benefit
DeferredRentLiabilityBenefit
238000
CY2013 cara Net Income Loss Available To Common Stockholders Basic And Diluted Per Share
NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedPerShare
-0.74
CY2013 cara License And Milestone Fees Revenue
LicenseAndMilestoneFeesRevenue
9637000
CY2013 cara Adjustment For Fair Value Liability Under License Agreement
AdjustmentForFairValueLiabilityUnderLicenseAgreement
35000
CY2013 cara Accrued Interest And Amortization Of Beneficial Conversion Feature On Promissory Notes
AccruedInterestAndAmortizationOfBeneficialConversionFeatureOnPromissoryNotes
3605000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-17642000
CY2014 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2014 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.85
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0057 pure
CY2014 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0 shares
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3988 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0303 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.713 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0523 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20965935 shares
CY2014 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
884000 shares
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20965935 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0164 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0272 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.649 pure
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20965935 shares
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0112 pure
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-17745000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
128000
CY2014 us-gaap Revenues
Revenues
3177000
CY2014 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
65586000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1371000
CY2014 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
139000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
393000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-18072000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
126000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7156000
CY2014 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-388000
CY2014 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
0
CY2014 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
0
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17745000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17946000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-201000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
1371000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
1371000
CY2014 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2014 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2023000
CY2014 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
0
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
40306000
CY2014 us-gaap Operating Expenses
OperatingExpenses
21249000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-42000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
57990000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15068000
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-201000
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-12000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
128000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6181000
CY2014 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2014 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
65586000
CY2014 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-201000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2055000
CY2014 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
57762000
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
783000
CY2014 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
100000
CY2014 cara Collaborative Revenue
CollaborativeRevenue
2201000
CY2014 cara Deferred Rent Liability Benefit
DeferredRentLiabilityBenefit
265000
CY2014 cara Effective Income Tax Rate Reconciliation Stock Option Shortfalls And Cancellations
EffectiveIncomeTaxRateReconciliationStockOptionShortfallsAndCancellations
-0.0069 pure
CY2014 cara Fair Value Transfers Between Levels One Two And Three
FairValueTransfersBetweenLevelsOneTwoAndThree
0 Securities
CY2014 cara Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-17745000
CY2014 cara Clinical Compound Revenue
ClinicalCompoundRevenue
674000
CY2014 cara Net Income Loss Available To Common Stockholders Basic And Diluted Per Share
NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedPerShare
-0.85
CY2014 cara License And Milestone Fees Revenue
LicenseAndMilestoneFeesRevenue
302000
CY2014 cara Stock Issued During Period Value Warrants Exercised Cashless
StockIssuedDuringPeriodValueWarrantsExercisedCashless
0
CY2014 cara Non Cash Or Part Non Cash Prepaid Initial Public Offering Costs Offset Against Proceeds Of Initial Public Offering
NonCashOrPartNonCashPrepaidInitialPublicOfferingCostsOffsetAgainstProceedsOfInitialPublicOffering
1465000
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>1. Business</b></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> Cara Therapeutics, Inc. (the &#x201C;Company&#x201D;) is a clinical-stage biopharmaceutical corporation formed on July&#xA0;2, 2004. The Company is focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. The Company&#x2019;s primary activities to date have been organizing and staffing the Company, developing its product candidates, including conducting preclinical studies and clinical trials of CR845-based product candidates and raising capital.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> As of December&#xA0;31, 2015, the Company has raised aggregate net proceeds of approximately $204,800 from several rounds of equity financing, including its initial public offering, or IPO, which closed in February 2014 and its follow-on offering, which closed in August 2015 (see Note 12, <i>Stockholders&#x2019; Equity</i>), and the issuance of debt. In addition, the Company earned approximately $32,500 under its license agreements for CR845, primarily with Maruishi Pharmaceutical Co. Ltd. (&#x201C;Maruishi&#x201D;) and Chong Kun Dang Pharmaceutical Corp. (&#x201C;CKD&#x201D;), and for an earlier product candidate for which development efforts ceased in 2007.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> In connection with the license of rights to CR845 in Japan to Maruishi and as part of the earnings described above, in April 2013, the Company received an upfront payment of $15,000, and in August 2014 and September 2015, the Company received an additional $480 and $1,725 (net of contractual foreign currency exchange adjustments), respectively, in milestone payments. In connection with the license of rights to CR845 in South Korea to CKD and as part of the earnings described above, in 2012, the Company received aggregate upfront and milestone payments of $1,190, and in August 2015 and October 2015, the Company received an additional $209 and $417 (net of South Korean withholding taxes), respectively, in milestone payments.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> As of December&#xA0;31, 2015, the Company had unrestricted cash and cash equivalents and marketable securities of $106,740 and an accumulated deficit of $104,891. The Company has incurred substantial net losses and negative cash flows from operating activities in nearly every fiscal period since inception and expects this trend to continue for the foreseeable future. The Company recognized a net loss of $24,690 and had net cash used in operating activities of $21,478 for the year ended December&#xA0;31, 2015. The Company expects that cash and cash equivalents and marketable securities at December&#xA0;31, 2015 will be sufficient to fund its operations beyond one year.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"> The Company is subject to risks common to other life science companies including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing, and compliance with Food and Drug Administration (&#x201C;FDA&#x201D;) and other government regulations. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability.</p> </div>
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-21478000
CY2015 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segments
CY2015 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2015 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2015 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
Tax years 2007 through 2015 remain open to U.S. federal and state tax examinations.
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.00
CY2015 dei Document Type
DocumentType
10-K
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0001346830
CY2015 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2004-07-02
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0041 pure
CY2015 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0 shares
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-25188000
CY2015 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"> <i>Concentrations of Credit Risk</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Financial instruments, which potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents and marketable securities. The Company invests its cash reserves in money market funds or high-quality marketable securities in accordance with its investment policy. The stated objectives of its investment policy is to preserve capital, provide liquidity consistent with forecasted cash flow requirements, maintain appropriate diversification and generate returns relative to these investment objectives and prevailing market conditions. The Company&#x2019;s investment policy includes guidelines on acceptable investment securities, limits interest-bearing security investments to certain types of debt and money market instruments issued by the U.S. government and institutions with investment grade credit ratings and places restrictions on maturities and concentration by asset class and issuer. The Company&#x2019;s cash, cash equivalents and marketable securities are held by a few major financial institutions. In accordance with the Company&#x2019;s policies, the Company monitors exposure with its counterparties. The Company also maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p> </div>
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.4107 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0314 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.674 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0595 pure
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2015 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 dei Entity Registrant Name
EntityRegistrantName
Cara Therapeutics, Inc.
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24620372 shares
CY2015 us-gaap Description Of Defined Contribution Pension And Other Postretirement Plans
DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
All employees over the age of 21 are eligible to participate in the plan after three consecutive months of service.
CY2015 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
774000 shares
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24620372 shares
CY2015 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2014-07-31
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0143 pure
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-12-31
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0189 pure
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <i>Use of Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with generally-accepted accounting principles in the United States (&#x201C;GAAP&#x201D;) requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, as of the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from the Company&#x2019;s estimates and assumptions. Significant estimates include the fair value of marketable securities that are classified as level 2 of the fair value hierarchy, useful lives of fixed assets, the periods over which certain revenues will be recognized, including licensing and collaborative revenue recognized from non-refundable up-front and milestone payments, the determination of prepaid research and development clinical costs and accrued research projects, the amount of non-cash compensation costs related to share-based payments to employees and non-employees and the periods over which those costs are expensed and the likelihood of realization of deferred tax assets.</p> </div>
CY2015 dei Trading Symbol
TradingSymbol
CARA
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.640 pure
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24620372 shares
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0158 pure
CY2015 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y11M23D
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20000
CY2015 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
80000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-24690000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
362000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-35000
CY2015 us-gaap Revenues
Revenues
3803000
CY2015 us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-35000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2514000
CY2015 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
184000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2489000
CY2015 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
101000
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
10317000
CY2015 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
18000
CY2015 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-35000
CY2015 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
5000
CY2015 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1442000
CY2015 us-gaap Royalty Revenue
RoyaltyRevenue
0
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements
0
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Sales
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales
0
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24725000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25087000
CY2015 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
91657000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-397000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
2514000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
2514000
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2015 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1452000
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
0
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-37562000
CY2015 us-gaap Operating Expenses
OperatingExpenses
28991000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-91677000
CY2015 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
0
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
75593000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21221000
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2015 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
80000
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-397000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3322000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
362000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7770000
CY2015 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-397000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1748000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
839000
CY2015 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
40000
CY2015 cara Completion Date Of Initial Public Offering One
CompletionDateOfInitialPublicOfferingOne
2014-02-05
CY2015 cara Collaborative Revenue
CollaborativeRevenue
2093000
CY2015 cara Deferred Rent Liability Benefit
DeferredRentLiabilityBenefit
289000
CY2015 cara Deferred Tax Expense Benefit From Stock Options Exercised
DeferredTaxExpenseBenefitFromStockOptionsExercised
-839000
CY2015 cara Effective Income Tax Rate Reconciliation Stock Option Shortfalls And Cancellations
EffectiveIncomeTaxRateReconciliationStockOptionShortfallsAndCancellations
-0.0003 pure
CY2015 cara Fair Value Transfers Between Levels One Two And Three
FairValueTransfersBetweenLevelsOneTwoAndThree
0 Securities
CY2015 cara Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-24690000
CY2015 cara Percentage Of Research And Development Tax Credits Exchanged For Cash
PercentageOfResearchAndDevelopmentTaxCreditsExchangedForCash
0.65 pure
CY2015 cara Clinical Compound Revenue
ClinicalCompoundRevenue
0
CY2015 cara Net Income Loss Available To Common Stockholders Basic And Diluted Per Share
NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedPerShare
-1.00
CY2015 cara License And Milestone Fees Revenue
LicenseAndMilestoneFeesRevenue
1710000
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-3383000
CY2014Q1 us-gaap Revenues
Revenues
178000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-4689000
CY2015Q1 us-gaap Revenues
Revenues
489000
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-3645000
CY2014Q2 us-gaap Revenues
Revenues
960000
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-5684000
CY2015Q2 us-gaap Revenues
Revenues
874000
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-6545000
CY2014Q3 us-gaap Revenues
Revenues
1125000
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-4787000
CY2015Q3 us-gaap Revenues
Revenues
2440000
CY2014Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-4172000
CY2014Q4 us-gaap Revenues
Revenues
914000
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-9530000

Files In Submission

Name View Source Status
0001193125-16-500345-index-headers.html Edgar Link pending
0001193125-16-500345-index.html Edgar Link pending
0001193125-16-500345.txt Edgar Link pending
0001193125-16-500345-xbrl.zip Edgar Link pending
cara-20151231.xml Edgar Link completed
cara-20151231.xsd Edgar Link pending
cara-20151231_cal.xml Edgar Link unprocessable
cara-20151231_def.xml Edgar Link unprocessable
cara-20151231_lab.xml Edgar Link unprocessable
cara-20151231_pre.xml Edgar Link unprocessable
d110352d10k.htm Edgar Link pending
d110352dex231.htm Edgar Link pending
d110352dex311.htm Edgar Link pending
d110352dex312.htm Edgar Link pending
d110352dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g110352figure1anew.jpg Edgar Link pending
g110352figure1b.jpg Edgar Link pending
g110352figure2new.jpg Edgar Link pending
g110352g83v28.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending